Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P-Gemox in Newly Diagnosed Extranodal NK/T-cell Lymphoma
NCT02533323Phase 2Terminated
- Sponsor
- Sun Yat-sen University
- Start
- Jan 2012
- Primary completion
- Sep 2016
- Modality
- DNA Intercalators/Alkylators, Therapeutic Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegaspargase, gemcitabine and oxaliplatin in Extranodal NK/T-cell lymphoma (ENKTL), sponsored by Sun Yat-sen University. Primary endpoint: Progression Free Survival at 3 years. Started Jan 2012; status: terminated.
02
Drugs
pegaspargasegemcitabineoxaliplatin
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT02533323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02533323.